Of Florida’s 30-member delegation, at least seven don’t own, buy or sell stocks, nor do their spouses or dependent children, a Playbook review of public records showed. They include GOP Reps. KAT ...

Whilst Pfizer was providing the medicines needed for the Union war effort, a young cavalry commander named Colonel Eli Lilly was serving in their army. A trained pharmaceutical chemist ...

The Indianapolis-headquartered pharmaceutical major was founded by a chemist, Colonel Eli Lilly. It is currently spread over 18 countries. The company is known for its clinical depression drugs ...

Eli Lilly’s total deal value with Rznomics could exceed $1.3 billion, plus royalties. Rznomics will lead early-stage research; Lilly to handle development and sales. Get access to the ...

While many pharma and biotech companies developing drugs to treat Alzheimer's disease are targeting amyloid beta plaque, Eli Lilly (NYSE:LLY) is looking at other targets as well. The drugmaker's ...

WestEnd Advisors LLC grew its position in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing ...

Eli Lilly (NYSE: LLY) has a strong pipeline of new medicines that could increase the stock price. *Stock prices used were the afternoon prices of May 15, 2025. The video was published on May 17, 2025.

If Eli Lilly’s latest ad is any indication, the drugmaker wants to differentiate itself from other pharma giants. How it intends to do so is by showcasing the company’s values and recruiting top ...

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from US rival Eli Lilly, makes inroads into its market share and as its pipeline of new ...

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal focused on treating hearing loss. The centerpiece of the agreement is ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have they changed positions in the annual IDEA Pharma Innovation Index ...